Title |
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene
|
---|---|
Published in |
BMC Cancer, November 2012
|
DOI | 10.1186/1471-2407-12-558 |
Pubmed ID | |
Authors |
Hisashi Tanaka, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Michiko Shimada, Akira Kurose, Shingo Takanashi, Ken Okumura |
Abstract |
Lung cancer is the leading cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitor (TKI) is used for the patients with EGFR-mutant lung cancer. Recently, phase III studies in the patients with EGFR-mutant demonstrated that EGFR-TKI monotherapy improved progression-free survival compared with platinum-doublet chemotherapy. The echinoderm microtubule-associated protein-like 4 (EML4)--anaplastic lymphoma kinase (ALK) fusion oncogene represents one of the newest molecular targets in non-small cell lung cancer (NSCLC). Patients who harbor EML4-ALK fusions have been associated with a lack of EGFR or KRAS mutations. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 29 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 17% |
Student > Master | 5 | 17% |
Other | 4 | 14% |
Researcher | 4 | 14% |
Student > Postgraduate | 4 | 14% |
Other | 7 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 52% |
Biochemistry, Genetics and Molecular Biology | 6 | 21% |
Agricultural and Biological Sciences | 3 | 10% |
Nursing and Health Professions | 2 | 7% |
Unspecified | 1 | 3% |
Other | 2 | 7% |